Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma

Phase 1

Completed

• Conditions: Patients With Intransit Stage III/IV Melanoma
• Interventions: Other: Isolated inferior limb perfusion

• Registration Number: NCT01213732
• Lead Sponsor: Philogen S.p.A.

Brief Summary

In this study the recombinant human fusion protein L19TNFα will be associated in ILP with the standard treatment with melphalan 10mg/l limb volume in subjects affected by stage III/IV limb melanoma.

The recombinant human fusion protein L19TNFα was created with the intention to target TNFα directly to tumor tissues with the result in high and sustained intralesional bioactive TNFα concentrations.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-10
• Study First Submitted: 2010-10-01
• Study First Submitted QC: 2010-10-01
• Study First Posted: 2010-10-04
• Primary Completion: 2011-03
• Status Verified: 2011-09
• Study Completion: 2011-09
• Last Update Submitted: 2022-04-08
• Last Update Posted: 2022-04-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

1. Subjects aged >18 years.
2. Histologically or cytologically confirmed intransit stage III/IV melanoma of lower extremity distal to the apex of the femoral triangle
3. ECOG performance status ≤ 2.
4. Subjects must have at least one unidimensional clinically measurable lesion as defined by RECIST criteria (see Section 8). This lesion must not have been irradiated within four weeks during previous treatments.
5. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and haemoglobin (Hb) ≥ 9.5 g/dl.
6. All acute adverse effects (excluding alopecia) of any prior therapy (including surgery, radiation therapy, chemotherapy) must have been resolved to ≤ Grade 1, except elevated liver transaminases judged to be associated with tumor infiltration (see below) (graded according to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events, version 3.0 [CTCAE, v.3.0].
7. Alkaline phosphatase (AP), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN), and total bilirubin ≤ 2.0 mg/dL unless liver involvement by the tumor, in which case the transaminase levels up to 5 x ULN are allowed.
8. Creatinine ≤ 1.5 ULN or 24 h creatinine clearance ≥ 60 mL/min.
9. Testing negative for acute or chronic infection with hepatitis B or C virus, or human immunodeficiency virus 1 or 2.
10. Negative pregnancy test for females of childbearing potential at the screening visit.
11. Commitment from subject to practice medically appropriate/acceptable method of birth control (e.g., hormonal, condoms or other adequate barrier controls, intrauterine contraceptive device, or sterilization) beginning at the screening visit and continuing until 3 months following the treatment with study drug
12. Able to provide written Informed Consent
13. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria

1. Breastfeeding women

2. Presence of active infections (e.g. requiring antimicrobial therapy) or other severe concurrent disease, which, in the opinion of the Investigator, would place the subject at undue risk or interfere with the study.

3. Active autoimmune disease.

4. Cardiac disease as manifested by any of the following:

   • > Grade II heart failure, graded per New York Heart Association (NYHA) criteria.
   • Unstable angina pectoris
   • Acute or subacute coronary syndromes, including myocardial infarction, occurring with 1 year prior to study treatment
   • Arrhythmia needing continuous treatment
   • Ejection fraction less than the institutional lower limit of normal as assessed by multigated radionuclide angiography (MUGA) scan or echocardiogram

5. Uncontrolled hypertension.

6. History of claudication or Ischemic peripheral vascular disease (Grade IIb-IV).

7. Chronic obstructive pulmonary disease or other chronic pulmonary disease with PFTs less than 50% predicted for age.

8. Symptomatic cerebrovascular disease.

9. Active peptic ulcer disease.

10. Concurrent infection of HIV.

11. Severe diabetic retinopathy.

12. Major surgery or trauma within 4 weeks prior to start of study treatment.

13. Hypersensitivity to melphalan or TNFα or other intravenously administered human proteins/peptides/antibodies.

14. Chemotherapy, radiation therapy or therapy with an investigational agent within 4 weeks prior to start of study treatment.

15. Any regional therapy to the affected extremity within 2 months prior to start of study treatment.

16. Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before administration of study treatment.

17. Growth factors or immunomodulatory agents within 7 days prior to the administration of study treatment.

18. Subject requires or is taking corticosteroids or other immunosuppressant drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.

19. Participation in another interventional clinical trial during participation in this trial.

20. Any conditions that in the opinion of the Investigator could hamper compliance with the study protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
L19TNFα plus melphalan	Isolated inferior limb perfusion	Subjects will be sequentially assigned to one of 2 dose levels of L19TNFα: 325 µg or 650 µg. All subjects will receive a single dose of L19TNFα and Melfalan (10mg/ L Limb volume).

Primary Outcome Measures

Name	Time	Method
Safety and Tolerability	6 weeks	The safety and tolerability profile of L19TNFα/melphalan combination treatment in the ILP setting will be determined.
Recommended dose (RD)	29 days	The recommended dose (RD) of L19TNFα when given in combination with melphalan in the ILP setting for subjects with limb stage III/IV melanoma will be determined.

Secondary Outcome Measures

Name	Time	Method
Objective response rate	10 weeks	Objective response rate of L19TNFα plus melphalan.
5-hydroxyindoleacetic acid	10 days	Assessment of plasma profile of 5-hydroxyindoleacetic acid (5-HIAA), a surrogate marker of vascular damage and tumor response.
Pharmacokinetic	10 days	Pharmacokinetic profile of L19TNFα when given with melphalan
Human anti-fusion protein antibody	6 weeks	Assessment of possible induction of human anti-fusion protein antibody \[HAFA\] formation
Antitumor activity	4- 6 weeks	Antitumor activity of L19TNFα plus melphalan (resection of residual tumor after 4- 6 weeks and histopathological response rate).

Trial Locations

Locations (2)

Fondazione IRCCS Istituto Nazionale dei Tumori; 🇮🇹 Milano, Italy

Azienda Ospedaliera Universitaria San Martino; 🇮🇹 Genova, Italy